13 VC firms investing in insurance and biotech & life sciences at the Series A stage.
F4 Fund tracks 13 VC firms that actively invest in insurance + biotech & life sciences at the Series A stage, with check sizes ranging from $100K – $500M (median: $3M – $3M). As of June 2026, and 92% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,358+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ Abstract Ventures Backing transformative founders building exceptional companies across all sectors San Francisco | $100K – $1M | 275 | Both | Active | — | — |
| 2 | ▶ Mundi Ventures Mundi backs bold, purpose-driven founders building technology companies at the intersection of deep tech and critical global challenges. Core thesis: Europe has world-class talent and ecosystem but suffers from a scale-up funding gap at growth stages. Kembara fund (€750M) bridges this by providing Series B/C growth capital to European deep tech and climate champions. Madrid | $1M – $40M | 53 | Leads | Active | ~2 mo | Open |
| 3 | ▶ Montage Ventures Montage Ventures aims to support radical thinkers who are bringing new ideas and platforms to foster change within the financial services, commerce and health sectors, leveraging AI as a key transformative agent. | $250K – $1M | 51 | — | 2mo | — | — |
| 4 | ▶ Vertical Venture Partners Back founders with deep, first-hand domain expertise in specific industry verticals — those who have 'lived' the problem they are solving. Vertical-first software delivers faster time-to-value and stronger retention versus horizontal tools requiring heavy customization. Palo Alto | $500K – $4M | 47 | Both | Active | ~1 mo | Open |
| 5 | ▶ AV8 Ventures Partner with visionary founders to build category-defining companies in healthcare, enterprise software, fintech/insurtech, and deep technology. Provide deep operational support, board participation, and access to domain expert network. Focus on companies solving problems in regulated or data-rich industries. Leverage Allianz's unique vantage point on risk, data, and regulation to identify opportunities at intersection of innovation and regulatory necessity. Palo Alto | $500K – $10M | 22 | Leads | Active | ~2 wks | Open |
| 6 | ▶ Boulder Ventures We invest in early-stage information technology and biotechnology companies in Colorado and the Mid-Atlantic. Our philosophy is rooted in mountain guide principles: careful pattern recognition under uncertainty, patience in waiting for proper conditions, and a commitment to realized returns over paper valuations. We provide hands-on operational partnership, board-level involvement, and access to deep regional networks built over decades. Boulder, Colorado | $1M – $5M | 22 | Leads | Active | ~1 mo | Req'd |
| 7 | ▶ Moderne Ventures Generalist investors with vertical expertise. We invest in bold, broad, multi-vertical technology companies applicable to multi-trillion dollar industries (real estate, finance, insurance, sustainability). Our distinctive Moderne Passport program creates value by connecting 1,500+ corporate executives with portfolio companies, generating customers, strategic partnerships, and operational guidance. Chicago | $2M – $25M | 21 | Leads | Active | ~2 wks | Req'd |
| 8 | ▶ Caffeinated Capital Support founders pursuing their life's work with an alternative to the hype cycle: the luxury of long-term thinking. We support founders building category-defining companies across all sectors that will last for lifetimes. San Francisco | $1M – $5M | 18 | Leads | Active | — | — |
| 9 | ▶ AIX Ventures AI-native companies where artificial intelligence is the core product and competitive moat, not just a feature. Three investment baskets: (1) AI infrastructure (vector databases, model serving, optimization), (2) vertical applications with 20%+ performance advantages, and (3) frontier research with clear commercialization paths. Palo Alto | $750K – $3M | 25 | Leads | Active | ~1 wk | Open |
| 10 | ▶ Debut Capital Early-stage venture capital for IT and Biotech companies in Colorado Front Range and Mid-Atlantic. Focus on experienced founding teams solving important problems with potential for significant financial returns. Patient capital approach with operational support and deep regional networks. New York | $500K – $5M | 48 | Leads | Active | ~2 wks | Req'd |
| 11 | ▶ Expa We build category-defining companies through a combination of design, product, operations, and capital. We identify market gaps, pair brilliant founders with Expa's studio resources, and help them build companies that reshape entire industries. San Francisco | $500K – $5M | 60 | Leads | Active | ~1 wk | Open |
| 12 | ▶ Cathay Innovation Startups positioned as transformation partners with Fortune 500 corporates create the most impactful solutions. We believe the next generation of market leaders will emerge through collaborative innovation between startups and incumbent enterprises, supported by global expertise and capital. Paris | $5M – $100M | 16 | Both | Active | ~1 mo | Req'd |
| 13 | ▶ Gigafund Back the world's most ambitious and transformative entrepreneurs capable of building world-defining companies over 20+ years. Invest in founders with independent thought and first-principles vision to solve humanity's biggest problems across all sectors and geographies. Austin | $1M – $500M | 18 | Leads | Active | 3+ mo | Open |
Investors on this page also frequently invest in these sectors
What other stages do these firms also invest in?
What other sectors do these firms also invest in?
F4 Fund tracks 13 VC firms that actively invest in insurance + biotech & life sciences at the Series A stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for series a insurance + biotech & life sciences investors is $3M – $3M, with a full range from $100K – $500M. The distribution breaks down as: 2 firms in the $500K-$1M range, 1 firms in the $1M-$2M range, 5 firms in the $2M-$5M range, 1 firms in the $5M-$10M range, 4 firms in the $10M+ range.
Among the 13 firms tracked, 92% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best series a insurance + biotech & life sciences investors combine domain expertise with an active portfolio in the space. Among these firms, 40% prefer warm introductions, and the average firm has 52 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.